Centiva Capital, LP Gilead Sciences, Inc. Call Options Transaction History

Centiva Capital, LP

$4.79 Billion
Q3 2024

Call Options

25 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $998,850 - $1.26 Million	15,000 Added 95.54%	30,700 $2.57 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $631,500 - $728,800	10,000 Added 175.44%	15,700 $1.08 Million
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $307,794 - $375,347	-4,300 Reduced 43.0%	5,700 $417,000
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $1.62 Million - $1.84 Million	-22,100 Reduced 68.85%	10,000 $810,000
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $1.63 Million - $1.78 Million	22,100 Added 221.0%	32,100 $2.41 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $760,100 - $867,000	-10,000 Reduced 50.0%	10,000 $770,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $1.87 Million - $2.68 Million	-30,000 Reduced 60.0%	20,000 $1.72 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $702,572 - $802,518	-11,800 Reduced 19.09%	50,000 $3.09 Million
Q2 2022 Aug 17, 2022	SELL	$57.72 - $65.01 $3.18 Million - $3.58 Million	-55,100 Reduced 47.13%	61,800 $3.82 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $4.29 Million - $5.37 Million	-74,000 Reduced 38.76%	116,900 $6.95 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $12.3 Million - $14 Million	190,230 Added 28392.54%	190,900 $13.9 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $1.31 Million - $1.41 Million	-19,330 Reduced 96.65%	670 $47,000
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $939,356 - $1.03 Million	14,800 Added 284.62%	20,000 $1.38 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $2.1 Million - $2.39 Million	-37,000 Reduced 87.68%	5,200 $302,000
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $589,950 - $741,760	9,500 Added 29.05%	42,200 $2.67 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $3.13 Million - $3.63 Million	-43,200 Reduced 56.92%	32,700 $2.52 Million
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $482,251 - $617,694	7,700 Added 11.29%	75,900 $5.67 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $3.26 Million - $3.59 Million	52,900 Added 345.75%	68,200 $4.43 Million
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $918,897 - $1.01 Million	14,700 Added 2450.0%	15,300 $970,000
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $4.92 Million - $5.52 Million	-79,600 Reduced 99.25%	600 $41,000
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $2.75 Million - $3.08 Million	44,000 Added 121.55%	80,200 $5.22 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $139,242 - $181,700	2,300 Added 6.78%	36,200 $2.27 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $1.28 Million - $1.41 Million	17,900 Added 111.87%	33,900 $2.62 Million
Q2 2018 Aug 03, 2018	SELL	$64.88 - $75.68 $64,879 - $75,680	-1,000 Reduced 5.88%	16,000 $1.13 Million
Q4 2017 Feb 06, 2018	BUY	$71.15 - $83.52 $1.21 Million - $1.42 Million	17,000	17,000 $1.22 Million

Others Institutions Holding GILD

# of Institutions

1,931

Shares Held

991M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.8 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.3 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.82 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.51 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.36 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $112B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.

Account